# SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

> **NCT04287179** · PHASE3 · WITHDRAWN · sponsor: **Novo Nordisk A/S**

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT04287179
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-03-09
- **Primary completion:** 2020-11-16
- **Final completion:** 2021-01-25
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** COVID19 impact on this trial was evaluated and a delay of at least 6-9 months was expected. In parallel, the development of a new type of pen injector, which was an important part of the trial, was ceased and thus this trial was cancelled.
- **Last updated:** 2022-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04287179

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04287179, "SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04287179. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*